AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-137. (Canceled)

138. (new) A compound selected from compounds of the following formulae and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:









wherein:

Ar is a group of the following formula:



wherein:

R^{SO} is independently C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl; and is optionally substituted; and

each of R^{3N}, R^{4N}, R^{5N}, R^{6N}, and R^{7N} is independently -H, or a group independently selected from:

hydroxy (-OH);

halo;

cyano (-CN);

carboxy (-COOH);

azido;

ester;

amino, including:

amino-C_{1-7}alkyl-amino;

C_{1-7}alkyl, including:

halo-C_{1-7}alkyl;

amino-C_{1-7}alkyl;

carboxy-C_{1-7}alkyl;

hydroxy-C_{1-7}alkyl;

C_{5-20}aryl-C_{1-7}alkyl;

ether, including:

C_{1-7}alkoxy;

halo-C_{1-7}alkoxy;

amino-C_{1-7}alkoxy;

carboxy-C_{1-7}alkoxy;

hydroxy-C_{1-7}alkoxy;

C_{5-20}aryl-C_{1-7}alkoxy;

acyl, including:

C_{1-7}alkyl-acyl;

halo-C_{1-7}alkyl-acyl;

amino-C_{1-7}alkyl-acyl;

carboxy-C_{1-7}alkyl-acyl;

hydroxy-C_{1-7}alkyl-acyl;

C_{5-20}aryl-C_{1-7}alkyl-acyl;

C_{5-20}aryl-acyl; and

C_{5-20}aryl;

the group $-OR^O$ is independently:

(a) -OH; or:

(b) an ether group; or:

(c) an acyloxy group;

each of R^2, R^3, R^5, and R^6, is independently:

(a) H; or:

(b) a monovalent monodentate substituent;

wherein each monovalent monodentate substituent, if present, is selected from:

hydroxy (-OH);

halo;

cyano (-CN);

carboxy (-COOH);

azido;

ester;

amino, including:

C_{1-7}alkyl-amino;

amino-C_{1-7}alkyl-amino;

C_{1-7}alkyl, including:

halo-C_{1-7}alkyl;

amino-C_{1-7}alkyl;

carboxy-C_{1-7}alkyl;

hydroxy-C_{1-7}alkyl;

C_{5-20}aryl-C_{1-7}alkyl;

ether, including:

C_{1-7}alkoxy;

halo-C_{1-7}alkoxy;

amino-C_{1-7}alkoxy;

carboxy-C_{1-7}alkoxy;

hydroxy-C_{1-7}alkoxy;

C_{5-20}aryl-C_{1-7}alkoxy;

acyl, including:

C_{1-7}alkyl-acyl;

halo-C_{1-7}alkyl-acyl;

amino-C_{1-7}alkyl-acyl;

carboxy-C_{1-7}alkyl-acyl;

hydroxy-C_{1-7}alkyl-acyl;

C_{5-20}aryl-C_{1-7}alkyl-acyl;

C_{5-20}aryl-acyl;

C_{5-20}aryl;

thiol (-SH); and,

thioether.

139. (new) A compound according to claim 138, wherein each monovalent monodentate substituent, if present, is selected from: hydroxy, halo, C_{1-7}alkoxy, thiol, and thioether.

140. (new) A compound according to claim 138, wherein each of R^{3N}, R^{4N}, R^{5N}, R^{6N}, and R^{7N} is independently -H or is selected from: hydroxyl, halo, C_{1-7}alkyl, and C_{1-7}alkoxy.

141. (new) A compound according to claim 139, wherein each of R^{3N}, R^{4N}, R^{5N}, R^{6N}, and R^{7N} is independently -H or is selected from: hydroxyl, halo, C_{1-7}alkyl, and C_{1-7}alkoxy.

142. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



143. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



144. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



145. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



146. (new) A compound according to claim 145, wherein each monovalent monodentate substituent, if present, is selected from: halo, thiol, and thioether.

147. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



148. (new) A compound according to claim 147, wherein each monovalent monodentate substituent, if present, is selected from: halo, thiol, and thioether.

149. (new) A compound according to claim 147, wherein one or both of R^3 and R^5 is a thiol or a thioether group.

150. (new) A compound according to claim 147, wherein each of R^3 and R^5 is a thiol or a thioether group.

151. (new) A compound according to claim 141, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

152. (new) A compound according to claim 142, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

153. (new) A compound according to claim 143, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

154. (new) A compound according to claim 144, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

155. (new) A compound according to claim 145, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

156. (new) A compound according to claim 147, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

157. (new) A compound according to claim 150, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

158. (new) A compound according to claim 141, wherein wherein R^{O} is -H.

159. (new) A compound according to claim 142, wherein wherein R^{O} is -H.

160. (new) A compound according to claim 143, wherein wherein R^{O} is -H.

161. (new) A compound according to claim 145, wherein wherein R^{O} is -H.

162. (new) A compound according to claim 147, wherein wherein R^{O} is -H.

163. (new) A compound according to claim 150, wherein wherein R^{O} is -H.

164. (new) A compound according to claim 151, wherein wherein R^O is -H.

165. (new) A compound according to claim 152, wherein wherein R^O is -H.

166. (new) A compound according to claim 153, wherein wherein R^O is -H.

167. (new) A compound according to claim 154, wherein wherein R^O is -H.

168. (new) A compound according to claim 155, wherein wherein R^O is -H.

169. (new) A compound according to claim 156, wherein wherein R^O is -H.

170. (new) A compound according to claim 157, wherein wherein R^O is -H.

171. (new) A compound selected from compounds of the following formulae and pharmaceutically acceptable salts, esters, solvates, and hydrates thereof:





wherein:

Ar is a group of the following formula:



and wherein:

each of R^3 and R^5, if present, is independently a thiol or thioether group;

R^O is independently -H;

R^{SO} is independently phenyl, and is optionally substituted; and

R^{5N} is independently -H, -OH, -F, -Cl, -Br, -I, -Me, -Et, -OMe, or -OEt.

172. (new) A compound selected from the following compounds and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof:
















Me
F






Me
O=S=O
N
O
OH


NMe2
O=S=O
N
O
OH


O
NMe2
O=S=O
N
O
OH


O
COOH
O=S=O
N
O
OH





173. (new) A compound selected from the following compound and pharmaceutically acceptable salts, esters, solvates, and hydrates thereof:



174. (new) A composition comprising a compound according to claim 138 and a pharmaceutically acceptable carrier or diluent.

175. (new) A method of treatment of colon cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

176. (new) A method of treatment of renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

177. (new) A method of treatment of breast cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

178. (new) A method of treatment of CNS cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

179. (new) A method of treatment of melanoma comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

180. (new) A method of treatment of colon cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

181. (new) A method of treatment of renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

182. (new) A method of treatment of breast cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

183. (new) A method of treatment of CNS cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

184. (new) A method of treatment of melanoma comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

185. (new) A method of treatment of colon cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

186. (new) A method of treatment of renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

187. (new) A method of treatment of breast cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

188. (new) A method of treatment of CNS cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

189. (new) A method of treatment of melanoma comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.